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Introduction	
	
Opioid	Addiction	and	Naloxone	
	
Since	its	harvesting	on	the	banks	of	the	Euphrates	during	the	Sumerian	empire,	opium	and	its	
related	products	have	entranced	and	entrapped	entire	communities	(1).	In	the	late	1990s,	the	
pharmaceutical	industry	aggressively	promoted	prescription	opioids	as	pain	relievers,	
misrepresenting	their	risks	of	addiction	(2).	Since	then,	these	medications	have	been	proved	to	
be	highly	addictive	and	many	Americans	are	struggling	with	and	dying	from	them	at	
skyrocketing	rates.	In	2015	over	2	million	people	suffered	from	substance	abuse	related	to	
prescription	opioid	pain	relievers	(3).	In	2017,	an	estimated	72,000	people	died	countrywide	
from	drug	overdose,	with	approximately	70%	of	these	deaths	involving	opioids	(4).	In	
Washtenaw	County,	55	people	from	January	to	August	2018	have	died	from	opioid-related	
overdose,	a	33%	increase	from	the	previous	year	(5).		
	
To	address	this	national	crisis,	multiple	strategies	have	been	put	forth.	Paramount	to	these	
efforts	is	the	idea	of	harm	reduction,	or	providing	patients	with	access	to	information	and	tools	
that	will	help	those	using	narcotics	or	accidentally	ingesting	them,	avoid	the	tragic	effects	of	
these	substances	(6).	To	this	aim,	Naloxone	has	been	instrumental	in	preventing	opioid-related	
overdose	death	not	only	in	the	community	but	also	in	the	hospital	setting	(7).	It	has	also	found	
uses	in	non-opioid	related	situations	such	as	traumatic	brain	injuries	(8).	
	
Purpose	of	Study	
	
On	September	7,	2017,	the	AMA	Opioid	Task	Force	issued	updated	guidance	“encouraging	
physicians	to	consider	co-prescribing	Naloxone	when	clinically	appropriate	for	patients	who	are	
at	risk	for	opioid	overdose	or	might	be	able	to	help	someone	at	risk”.	In	the	same	article,	Dr.	
Sarah	Wakeman	states	“co-prescribing	Naloxone	is	important	to	ensure	all	people	being	
prescribed	opioids	at	risk	for	overdose	have	this	lifesaving	medication	at	home,	similar	to	how	
we	might	think	about	co-prescribing	glucagon	to	someone	with	insulin-dependent	diabetes”	
(9).		
 
Yet,	despite	its	obvious	benefits	and	the	absence	of	side	effects,	many	medical	providers	still	
express	ambivalence	regarding	prescribing	Naloxone	(10).	Adding	to	the	confusion	is	the	fact	
that	in	multiple	states,	including	Michigan,	Naloxone	is	supposed	to	be	available	over	the	
counter	at	pharmacies	(though	in	practice	often	is	not).	As	a	result,	many	providers	may	not	
believe	it	is	necessary	for	them	to	prescribe	Naloxone.	
	
Nonetheless,	given	the	scope	of	opioid-related	deaths	both	county	and	countrywide,	it	is	
essential	that	physicians	prescribe	Naloxone	often	and	freely.	Indeed,	a	study	performed	in	
2017	showed	that	providers	who	had	received	Naloxone	education	were	eleven	times	more	
likely	to	prescribe	it	to	their	patients	compared	to	those	who	had	not	received	such	education	
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(11).	Before	interventions	can	educate,	however,	it	is	important	to	understand	the	current	
prescription	practices	and	attitudes	of	providers.	To	this	aim,	the	following	survey	was	
conducted	in	conjunction	with	the	Addiction	Psychiatry	department	and	distributed	
electronically	to	residents	at	the	University	of	Michigan.	The	goal	of	the	survey	was	to	ascertain	
resident	prescription	practices	and	attitudes	towards	Naloxone.	
	
Methods	
	
This	was	an	IRB-exempt,	anonymous	survey	using	Google	Qualtrics,	an	internet-based	data	
collection	program.	The	study	population	was	103	residents	from	multiple	programs	at	the	
University	of	Michigan.	Program	directors	were	contacted	and	asked	to	send	the	survey	link	to	
their	residents.	There	was	one	follow-up	email	reminder	to	residents	to	fill	out	the	survey.	The	
survey	collected	individual	residency	program,	residency	program	year,	and	answers	to	35	
multiple-choice	questions	regarding	prescription	practices	and	attitudes	towards	Naloxone.	The	
survey	choices	for	prescription	practices	of	Naloxone	were	varied,	but	for	the	Inpatient	and	
Outpatient	sections	were:		N/A,	0%,	1-10%,	11-25%,	26-50%,	51-100%.	The	survey	choices	for	
attitudes	towards	Naloxone	were:		Strongly	Disagree,	Disagree,	Neutral,	Agree,	Strongly	Agree.		
	
Data	Curation	
	
Prior	to	doing	the	survey	analysis,	it	was	necessary	to	carry	out	a	few	data	curation	steps	on	the	
raw	returned	forms,	related	to	missing	or	invalid/inconsistent	answers.	In	a	number	of	cases	for	
example,	particularly	for	the	Attitudes	and	Inpatient/Outpatient	questions,	there	were	a	small	
number	of	missing	answers.	For	the	Attitudes	questions,	with	5	choices	from	“Strongly	
Disagree”	to	“Strongly	Agree”,	I	filled	in	the	missing	responses	with	the	default	“Neutral”	value.	
Likewise,	for	the	Inpatient/Outpatient	series	of	questions,	with	percentage	choices	or	“N/A”	as	
responses,	I	filled	in	any	missing	responses	with	the	default	“N/A”	value,	as	the	most	likely	
intended	response.	
	
Beyond	this,	there	were	problems	with	questions	Q4	(“Have	you	ever	prescribed	a	Naloxone	
rescue	kit?”),	Q8	(“If	you	have	prescribed	Naloxone	before,	in	what	setting	was	it?”),	and	to	a	
lesser	extent,	Q5	(“If	you	have	prescribed	Naloxone	previously,	how	did	you	provide	the	
prescription?”)—which	contributed	to	the	appearance	of	some	anomalous	responses.	
	
In	the	case	of	Q4,	the	use	of	the	term	“Naloxone	rescue	kit”	confused	some	(13)	respondents	as	
being	a	specialized	form	of	Naloxone	product	with	which	they	were	not	familiar	(and	thus	
answered	“No”),	instead	of	meaning	any	Naloxone	product	in	general.	The	confusion	became	
obvious	by	looking	at	their	subsequent	answers	to	Q5-Q8,	which	clearly	indicated	that	they	had	
indeed	prescribed	some	form	of	Naloxone.	For	these	13	cases,	I	decided	to	modify	their	Q4	
responses	from	“No”	to	a	new	category	(“Yes”),	indicating	that	they	had	prescribed	Naloxone,	
but	with	an	unspecified	`number	of	times’	count.	
	
In	the	case	of	Q8,	I	should	have	provided	a	default	option	“I	have	not	prescribed	Naloxone”,	as	I	
had	for	Q5,	Q6,	and	Q7.	This	was	an	oversight.	Many	respondents	justifiably	skipped	this	
question;	others	appeared	to	simply	fill	in	the	type	of	setting	“Inpatient/ED”	or	“Outpatient”	in	
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which	they	were	working.	By	examining	the	skips	and	their	responses	to	Q4-Q7,	I	was	able	to	
accurately	reconstruct	the	effective	“I	have	not	prescribed	Naloxone”	option/responses	for	Q8.	
	
Finally,	in	the	case	of	Q5,	the	question	asks	how	the	prescription	was	provided,	with	the	options	
“Script	for	pharmacy”,	“Naloxone	given	directly	to	patient”,	or	“Other”.	It	might	have	been	
better	to	ask	“How	was	the	Naloxone	provided?”,	because	in	4	cases	out	of	14	where	
“Naloxone	given	directly	to	patient”	was	selected	for	Q5,	in	Q6	and	Q7	one	of	these	was	
marked	“I	have	not	prescribed	Naloxone”	while	the	other	was	marked	“The	use	of	Naloxone	
was	not	explained”	(Q6)	or	“Instructions	were	not	provided”	(Q7)—presumably	under	the	
(unintended)	interpretation	that	if	the	Naloxone	was	given	directly	to	the	patient	(for	example	
in	the	ED),	then	technically	there	was	no	prescription.		
	
The	intention	of	Q5	was	to	consider	both	a	script,	or	the	Naloxone	directly,	as	alternative	forms	
of	‘prescribing	Naloxone’,	and	thus	to	make	these	4	cases	consistent	with	the	others	of	this	
type,	I	replaced	the	“I	have	not	prescribed	Naloxone”	responses	(option	1)	in	Q6	and	Q7,	with	
the	corresponding	option	2	above	(“use	not	explained”,	or	“instructions	not	provided”)	for	Q6	
(twice)	and	Q7	(twice),	respectively.	
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Respondents	
		
A	total	of	103	residents	responded	to	the	survey;	individual	respondents	were	characterized	by	
two	variables,	Residency	Program	and	Program	Year.	
	
Participating	Programs	and	Years	
	
	
	
R0	-	Please	check	which	program(s)	you	are	a	resident	of	
	
As	illustrated	above,	22	residency	programs	were	invited	to	participate	in	the	survey;	15	
returned	responses.	Of	these,	2	returned	20	or	more	responses	(Anesthesiology	and	Internal	
Medicine),	2	others	returned	10	or	more	(Psychiatry	and	Surgery),	and	3	others	returned	at	
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least	5	(Internal	Medicine-Pediatrics,	Pediatrics	and	Communicable	Diseases,	and	Physical	
Medicine	and	Rehabilitation).		
	
	
	
R1	-	Please	select	your	year	of	residency	
	
The	chart	above	shows	the	distribution	of	program	years	across	all	103	respondents.	The	
largest	numbers	(almost	80%)	are	from	the	first	three	residency	years.		
	
Analysis	Overview	
	
In	the	sections	that	follow,	the	results	are	summarized	for	all	35	survey	questions,	subdivided	
into	four	subsets.	The	chart	for	each	survey	question	or	pair,	over	all	participants,	is	displayed	
first,	followed	by	summary	comments	for	the	entire	group	along	with	major	characteristics	and	
differences	in	the	responses	of	the	(larger)	program	groups.	In	order	to	respect	survey	
anonymity,	I	have	not	subdivided	observations	about	responses	within	specific	programs	by	the	
exact	residency	year.	
	
Finally,	for	most	questions,	the	total	number	of	responses	is	103	(one	per	survey),	but	there	are	
several	questions	(Q1,	Q2,	Q3,	Q6,	Q7,	Q8)	where	multiple	responses	were	allowed,	so	that	the	
total	is	greater	than	103.	 	
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Basic	Practices	Questions	(Q1	-	Q8)	
	
The	Basic	Practices	questions	cover	naloxone	administration,	prescriptions,	and	the	provision	of	
explanations	and	instructions	to	the	patient	regarding	its	usage.	
	
Q1-2	Naloxone	Administration	
	
	
	
Q1:	Have	you	previously	received	training	about	the	administration	of	naloxone	to	reverse	
opioid	overdose?	If	so,	where?	(check	all	that	apply)	
	
	
	
Q2:	Have	you	ever	administered	naloxone?	If	so,	where?	(check	all	that	apply)	
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Q1	–	Almost	40%	of	the	103	respondents	have	not	had	Naloxone	administration	training;	the	
remaining	63	did,	primarily	during	residency	(41%	of	the	total)	or	while	in	medical	school	
(37%)—or	both	(21%).	Most	of	the	‘No’	responses	came	from	Anesthesiology	(25%	of	program	
respondents,	PG-Years	1&2),	Dermatology	(1	of	1),	Internal	Medicine	(about	50%,	mostly	PG-
Years	1&2),	Neurology	(3	of	3),	Psychiatry	(about	50%),	and	Radiation	Oncology	(2	of	2).	
	
Q2	–		Regarding	administration,	55%	of	the	103	respondents	have	not	administered	Naloxone;	
of	the	rest	(46),	the	location	was	primarily	in	an	inpatient	setting	(37%	of	the	total),	and	
secondarily	in	the	Emergency	Department	(15%)—or	both	(7%).	The	main	disciplines	reporting	
administration	of	Naloxone	included	Anesthesiology,	Internal	Medicine	(including	IM-
Pediatrics),	Physical	Medicine,	and	Surgery.	
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Q3-5,8	Naloxone	Prescription	
	
	
	
Q3:	Have	you	ever	received	training/education	about	naloxone	prescribing?	If	so,	where?	(check	
all	that	apply)	
	
	
	
Q4:	Have	you	ever	prescribed	a	naloxone	rescue	kit?	If	so,	how	many	times?	
56
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Q3	- Received	Naloxone	Prescription	 Training?
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Q3	–	About	54%	of	the	103	respondents	have	not	received	Naloxone	prescription	training;	of	
the	rest	(47),	33%	of	the	total	received	it	during	Residency,	and	21%	during	medical	school—or	
both	(9%).	The	respondents	that	had	not	received	training	came	primarily	from	Anesthesiology	
(about	60%	of	program	respondents,	mostly	from	PG-Years	1&2),	Internal	Medicine	(60%,	
mostly	PG-Years	2&3),	Neurology	(2	of	3),	Obstetrics/Gyn	(3	of	3),	Pediatrics	(6	of	7),	Physical	
Medicine	(3	of	6),	and	Surgery	(50%	of	program	respondents,	mostly	later	PG-Years,	4-7).	The	
program	with	the	highest	rate	of	respondents	reporting	Naloxone	prescription	training	was	
Psychiatry	(almost	75%),	followed	by	IM-Pediatrics	(4	of	6).	
	
Q4	–	Close	to	60%	of	the	103	respondents	have	not	prescribed	any	form	of	Naloxone;	of	the	
rest	(43),	13%	did	prescribe	it	in	some	form	(not	considered	to	be	a	‘kit’),	but	with	no	count	[see	
comments	in	Data	Curation	section	of	the	Introduction],	while	almost	30%	have	prescribed	it	
one	or	more	times.	The	7	respondents	who	prescribed	it	5	or	more	times	were	from	several	
programs—Internal	Medicine	(2),	IM-Pediatrics,	Neurology,	Orthopedic	Surgery,	and	Psychiatry	
(2).	By	far	the	program	with	the	most	instances	of	prescriptions	was	Psychiatry,	followed	by	
Internal	Medicine,	and	Orthopedic	Surgery.	
	
Considering	the	60	of	103	respondents	who	had	not	prescribed	Naloxone	at	all	[which	is	also	
directly	applicable	to	Questions	5,	6,	7,	and	8],	most	were	from	Anesthesiology	(71%	of	
program	respondents),	Dermatology	(1	of	1),	Internal	Medicine	(55%),	Obstetrics/Gyn	(3	of	3),	
Pediatrics	(7	of	7),	Radiation	Oncology	(2	of	2),	and	Surgery	(80%).	
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Q5:	If	you	have	prescribed	naloxone	previously,	how	did	you	provide	the	prescription?	
	
	
	
	
	
Q8:	If	you	have	prescribed	Naloxone	before,	in	what	setting	was	it?	(check	all	that	apply)	
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Q5	–	Of	the	more	than	40%	of	the	103	respondents	that	provided	Naloxone	to	patients,	about	
2/3	wrote	prescriptions,	while	the	rest	gave	Naloxone	directly	to	the	patient.	The	programs	that	
primarily	provided	pharmacy	scripts	were	Internal	Medicine	(also	IM-Pediatrics),	and	
Psychiatry.	Anesthesiology	and	Surgery	were	more	likely	to	give	the	drug	directly	to	the	patient.	
	
Q8	–	Likewise,	of	the	more	than	40%	that	provided	Naloxone	to	patients,	about	2/3	did	so	in	an	
Inpatient/ED	setting,	and	the	remaining	in	an	Outpatient	or	other	setting.	
	
Given	the	similarity	of	the	Q5	and	Q8	charts,	one	might	guess	that	Naloxone	is	normally	given	
directly	in	the	Outpatient	setting,	and	via	written	prescription	in	the	Inpatient/ED	setting.	This	
turned	out	not	to	be	true,	but	it	was	true	that	scripts	were	almost	always	provided	in	the	
Outpatient	setting,	and	likewise	when	Naloxone	was	given	directly	to	the	patient,	it	was	almost	
always	in	an	Inpatient/ED	setting.	
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Q6-7	Explanations/Instructions	
	
	
	
Q6:	If	you	have	prescribed	Naloxone	previously,	was	the	purpose	of	its	use	explained	to	the	
patient?	If	so,	by	whom?	(check	all	that	apply)	
	
	
	
	
Q7:	If	you	have	prescribed	Naloxone	previously,	were	instructions	provided	to	the	patient	as	to	
how	to	use	Naloxone?	If	so,	by	whom	and	how?	(check	all	that	apply)	
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Q6	–	Of	42%	of	total	respondents	that	provided	Naloxone,	the	purpose	of	the	drug	was	
explained	to	the	patient	about	80%	of	the	time,	in	a	variety	of	ways	but	most	commonly	by	the	
resident	respondent,	or	a	nurse,	or	via	written	instructions.	There	were	no	clear	differences	
between	programs	except	that	Internal	Medicine	and	Psychiatry	cited	a	wider	set	of	options	as	
to	how	the	explanation	was	provided.	
	
Q7	–	Similarly,	of	the	42%	percent	that	provided	Naloxone,	instructions	for	its	use	were	
provided	to	the	patient	about	80%	of	the	time,	most	commonly	via	written	instructions,	or	by	a	
nurse,	or	the	resident	respondent.	Again,	Internal	Medicine	and	Psychiatry	cited	a	wider	set	of	
options	as	to	how	the	instructions	were	provided	compared	to	other	programs—probably	due	
to	having	more	instances	of	prescribing	the	drug.	
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Inpatient	Setting	Questions	(Q9	-	Q14)	
	
The	Inpatient	Setting	questions	cover	what	percentages	of	patients	in	this	setting	use	or	misuse	
non-/prescription	opioids,	and	how	many	received	Naloxone	and	instructions	for	how	to	use	it.	
	
Q9-10	Inpatient	Opioid	Users	
	
	
	
Q9:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	over	the	last	year	used	
prescription	opioids	(vicodin,	percocet,	oxycodone,	demerol,	dilaudid,	fentanyl,	morphine,	codeine,	etc.)?	
	
	
	
Q10:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	over	the	last	year	
used	opioids	not	obtained	from	a	prescription?	
6
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Q9	–	In	the	inpatient	setting,	around	95%	of	respondents	reported	prescription	opioid	use	by	
some	non-zero	percentage	of	patients,	with	the	most	common	answer	(34%	of	all	respondents)	
being	11-25%,	followed	by	25-50%	(24%),	51-100%	(20%),	and	then	1-10%	(16%).	Not	
surprisingly	the	higher	percentages	of	patients	were	found	especially	in	Orthopedic	Surgery	and	
Surgery,	with	intermediate	percentages	in	Anesthesiology,	Internal	Medicine,	IM-Pediatrics,	
Neurology,	Obstetrics/Gyn,	and	Physical	Medicine,	and	lower	amounts	in	Pediatrics	and	
Psychiatry.	The	6	N/A	responses	came	from	Dermatology	(1	of	1),	Radiation	Oncology	(2	of	2),	
Radiology	(1	of	2),	and	Anesthesiology	(2	of	24).	
	
Q10	–	The	inpatient	picture	is	significantly	different	for	non-prescription	opioid	use.	There	are	
now	24	N/A	responses,	most	new	ones	(9)	coming	from	Anesthesiology,	with	some	from	
Pediatrics,	Physical	Medicine,	and	a	few	other	disciplines.	Of	the	other	79	(77%)	respondents,	
by	far	the	most	frequent	answer	(62%	of	103)	was	1-10%,	meaning	a	small	percentage	of	
patients	using	non-prescription	opioids,	followed	by	11-25%	(9%),	with	the	higher	percentages	
reported	in	Internal	Medicine,	Surgery,	and	Orthopedic	Surgery.	
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Q11-12	Inpatient	Opioid	Misusers	
	
	
	
Q11:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	using	opioids	over	
the	last	year	misused	prescription	opioids?	
	
	
	
	
Q12:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	using	opioids	over	
the	last	year	misused	opioids	not	obtained	from	a	prescription?	
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Q11	–	With	regard	to	inpatients	who	misused	prescription	opioids,	the	Q11	chart	shows	fairly	
low	percentages	overall,	with	a	distribution	quite	similar	in	fact	to	the	reported	user	
percentages	of	non-prescription	opioids	in	the	previous	Q10	chart.	There	are	18	N/A	responses,	
and	after	that	58%	of	the	103	overall	responses	were	for	1-10%,	a	small	percentage	of	patients,	
followed	by	16%	reporting	11-25%	levels.	Higher	percentages	of	patients	were	reported	by	
participants	in	Internal	Medicine,	Surgery,	and	Orthopedic	Surgery.	The	largest	number	of	N/A	
responses	(10)	were	found	in	Anesthesiology.	
	
Q12	–	For	the	case	of	inpatients	who	misused	non-prescription	opioids,	the	distribution	of	
responses	is	somewhat	similar.	There	are	now	28	N/A	responses,	an	additional	10	from	Q11,	
distributed	across	the	most	numerous	services	(except	Psychiatry).	The	most	common	value	
reported	is	again	1-10%	of	patients,	by	a	similar	percentage	of	total	respondents	(59%),	with	
the	next	highest	report	of	11-25%	(7%	of	respondents).	The	higher	percentage	responses	are	
again	mostly	found	in	Internal	Medicine,	Surgery	and	Orthopedic	Surgery.	The	highest	numbers	
of	N/A	responses	are	likewise	in	Anesthesiology	(12),	with	others	from	fields	including			
Dermatology	(1	of	1),	Physical	Med	(4	of	6),	Radiation	Oncology	(2	of	2),	and	Urology	(1	of	1).	
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Q13-14	Inpatient	User/Misusers	&	Naloxone	
	
	
	
Q13:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	over	the	last	year	
that	used	or	misused	opioids	received	a	Naloxone	prescription?	
	
	
	
	
Q14:	In	the	inpatient/ED	setting,	approximately	how	many	of	your	patients	over	the	last	year	
that	used	or	misused	opioids	received	Naloxone	use	instruction?	
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Q13	–	Question	13	concerns	what	percentage	of	all	opioid	inpatients	received	a	Naloxone	
prescription.	There	were	41	N/A	responses,	the	largest	group	coming	from	Anesthesiology	(17,	
or	71%	of	the	program	respondents),	with	others	scattered	across	multiple	disciplines	(except	
Psychiatry).	Of	the	remaining	62	respondents,	the	most	common	response	(28%	of	103	total)	
was	‘0’—meaning	none	of	the	patients	received	Naloxone.	Most	of	these	zeros	came	from	
respondents	in	Internal	Medicine,	IM-Pediatrics,	Pediatrics,	and	Surgery.	The	next	highest	
answer	was	1-10%	(22%	of	respondents),	dropping	sharply	from	there	for	the	higher	patient	
percentages.	The	highest	patient	percentage	responses	came	from	Psychiatry,	which	by	far	had	
the	highest	average	percentage	of	patients	receiving	Naloxone	prescriptions.	
	
Q14	–	Results	were	similar	for	Question	14,	related	to	what	percentage	of	all	opioid	inpatients	
received	Naloxone	use	instruction.	Here	the	number	of	N/A	responses	increased	by	11	to	52	
(50%	of	total	respondents),	with	the	main	additions	coming	from	Anesthesiology	and	Internal	
Medicine	(3	each).	Of	the	remaining	51	responses,	the	most	common	answer	was	again	‘0’	
(26%	of	103	total),	and	secondarily	1-10%	(14%).	The	zero	responses	were	mostly	from	Internal	
Medicine	and	IM-Pediatrics.	The	higher	patient	percentage	responses	were	again	largely	
associated	with	Psychiatry.	
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Outpatient	Setting	Questions	(Q15	-	Q20)	
	
The	Outpatient	Setting	questions	cover	what	percentages	of	patients	in	this	setting	use	or	
misuse	non-/prescription	opioids,	and	how	many	received	Naloxone	and	instructions	to	use	it.	
	
Q15-16	Outpatient	Opioid	Users	
	
	
	
Q15:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	over	the	last	year	used	
prescription	opioids?	
	
	
	
Q16:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	over	the	last	year	used	
opioids	not	obtained	from	a	prescription?	
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Q15	–	In	the	outpatient	setting,	around	63%	of	respondents	reported	prescription	opioid	use	by	
some	non-zero	percentage	of	patients,	with	the	most	common	answer	(25%	of	all	respondents)	
being	1-10%,	followed	by	11-25%	(17%),	26-50%	(11%),	and	50-100%	(9%).	The	higher	
percentages	of	patients	were	primarily	found	in	Anesthesiology,	Orthopedic	Surgery,	Radiation	
Oncology	and	Surgery,	with	intermediate	levels	for	Internal	Medicine,	Physical	Medicine,	and	
Psychiatry.	In	addition,	there	were	many	more	N/A	responses	to	this	outpatient	setting	
question	compared	to	the	same	question	for	inpatients	(Q9)—35	vs.	6.	By	far	the	largest	group	
of	these	was	in	Anesthesiology	(75%	of	program	respondents),	followed	by	Psychiatry	(45%),	
and	Surgery	(40%).	
	
Q16	–	The	outpatient	picture	is	somewhat	different	for	non-prescription	opioid	use.	There	are	
now	11	more	N/A	responses,	46	vs.	35,	with	the	new	ones	scattered	across	disciplines.	In	
addition	there	are	more	‘0’	responses,	12	vs.	4,	and	more	of	the	most	common	1-10%	response,	
39	vs.	26,	with	a	corresponding	reduction	in	the	higher	level	percentages.	When	compared	to	
the	matching	inpatient	question	(Q10),	the	main	differences	with	the	outpatient	answers	are	
more	N/A	and	0	responses	for	the	outpatients,	with	correspondingly	lower	counts	for	the	most	
common	1-10%	response	(39	vs.	64).	
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Q17-18	Outpatient	Opioid	Misusers	
	
	
	
Q17:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	using	opioids	over	the	
last	year	misused	prescription	opioids?	
	
	
	
	
Q18:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	using	opioids	over	the	
last	year	misused	opioids	not	obtained	from	a	prescription?	
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Q17	–	With	regard	to	outpatients	who	misused	prescription	opioids,	the	Q17	chart	shows	low	
percentages	overall,	with	a	distribution	quite	similar	to	the	reported	user	percentages	of	non-
prescription	opioids	in	the	previous	Q16	chart	(much	like	the	inpatient	case).	There	are	45	N/A	
responses,	and	after	that	36%	of	the	103	overall	responses	were	for	1-10%,	indicating	a	low	
percentage	of	patients,	followed	by	10%	reporting	11-25%	levels.	Higher	percentages	of	
patients	were	mostly	found	in	Internal	Medicine,	Psychiatry,	and	Surgery.	The	highest	average	
percentage	of	such	patients	was	in	Internal	Medicine.	The	largest	number	of	N/A	responses	(20,	
83%	of	program	responses)	were	found	in	Anesthesiology,	followed	by	Psychiatry	(45%),	and	
Surgery	(40%).	Compared	to	the	corresponding	inpatient	chart	(Q11),	the	Q17	outpatient	chart	
has	considerably	more	N/A	responses	(45	vs.	18),	and	inversely	fewer	1-10%	(37	vs.	60),	and	11-
25%	(10	vs.	16)	responses.	
	
Q18	–	For	the	case	of	outpatients	who	misused	non-prescription	opioids,	the	distribution	of	
responses	is	somewhat	similar	to	the	prescription	opioids	case	above	it	in	Q17.	There	are	
several	less	11-25%	responses,	and	a	few	more	N/A	and	‘0’	responses.	The	number	of	N/A	
responses	is	now	50,	again	mostly	concentrated	in	Anesthesiology	(88%	of	program	
respondents),	Surgery	(60%),	Physical	Medicine	(50%),	and	Psychiatry	(45%).	There	are	‘0’	
responses	in	Neurology	(3	of	3),	Pediatrics	(3	of	6),	and	others	scattered	elsewhere.	The	most	
common	patient	percentage	response	is	again	1-10%	(37,	or	36%	of	the	103	total	responses).	
The	very	few	higher	patient	percentage	responses	are	scattered	over	different	services.	The	
differences	between	this	Q18	chart	for	outpatients	and	the	corresponding	Q12	chart	for	
inpatients,	include	many	more	N/A	and	some	‘0’	responses	for	the	outpatient	case,	and	far	
fewer	1-10%	and	some	11-25%	responses,	than	for	the	inpatient	case.	
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Q19-20	Outpatient	User/Misusers	&	Naloxone	
	
	
	
Q19:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	using	opioids	over	the	
last	year	that	used	or	misused	opioids	received	a	Naloxone	prescription?	
	
	
	
	
Q20:	In	the	outpatient	setting,	approximately	how	many	of	your	patients	over	the	last	year	that	
used	or	misused	opioids	received	Naloxone	use	instruction?	
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Q19	–	Question	19	concerns	what	percentage	of	all	opioid	outpatients	received	a	Naloxone	
prescription.	There	were	54	N/A	responses,	the	largest	group	coming	from	Anesthesiology	(21,	
or	88%	of	the	program	respondents),	followed	by	Surgery	(60%),	Physical	Medicine	(3	of	6),	
Orthopedic	Surgery	(2	of	4),	Psychiatry	(45%),	Pediatrics	(3	of	7),	and	Internal	Medicine	(35%).	
Of	the	other	49	responses,	the	most	common	answer	was	‘0’	(25%	of	total),	followed	by	1-10%	
(14%),	with	only	a	few	higher	percentages.	The	zero	responses	were	scattered	across	
disciplines;	most	of	the	non-zero	responses	were	found	in	Internal	Medicine	(8),	followed	by	
Psychiatry	(4)	and	Anesthesiology	(3).	Compared	to	the	corresponding	inpatient	chart	(Q13),	
the	outpatient	case	had	13	more	N/A	responses,	with	corresponding	small	decreases	in	the	‘0’,	
1-10%,	and	11-25%	answers.	
	
Q20	–	Results	were	similar	for	Question	20,	concerning	what	percentage	of	all	opioid	
outpatients	received	Naloxone	use	instruction.	Small	increases	in	the	N/A	and	‘0’	responses	for	
Q20,	were	compensated	by	fewer	responses	of	1-10%	compared	to	Q19.	The	most	changes	
were	seen	in	Internal	Medicine.	Compared	to	the	corresponding	inpatient	case	(Q14),	the	
outpatient	chart	shows	a	few	more	N/A	and	‘0’	responses,	and	a	few	less	higher	percentage	
responses	(11-25%,	26-50%,	and	50-100%).	
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Attitudes	Questions	(Q21	-	Q35)	
	
The	Attitudes	questions	cover	opinions	related	to	Naloxone	intervention,	availability,	and	risks,	
along	with	resident	confidence	in	providing	Naloxone,	and	the	level	of	institutional	use.	
	
Q21-23	Intervention	
	
	
	
Q21:	Naloxone	is	a	lifesaving	intervention	for	patients	that	misuse	opioids	
	
	
	
Q22:	I	feel	comfortable	administering	Naloxone	in	an	overdose	situation	
	 29	
	
Q21	–	The	first	of	the	Attitudes	questions	asks	if	Naloxone	is	a	lifesaving	intervention	for	those	
who	misuse	opioids.	There	is	stunning	agreement	on	this	question;	98	(95%)	of	respondents	
either	agreed	or	strongly	agreed	with	the	statement,	with	only	2	strong	disagreements	and	3	
neutral	responses	(5%	total).	These	5	responses	all	appear	in	different	specialties.	
	
Q22	–	The	next	question	asks	about	feeling	comfortable	in	administering	Naloxone	for	
overdoses.	The	answers	here	are	more	balanced,	but	favor	agreement.	A	total	of	53	(51%)	
answered	agree	or	strongly	agree	to	this	question,	while	21	(20%)	answered	disagree	or	
strongly	disagree,	and	there	were	29	(28%)	neutral	responses.	Adding	the	disagreements	with	
the	neutrals	gives	49%	that	are	not	definitively	comfortable	about	administering	the	drug	for	
overdose	situations.	These	50	responses	are	distributed	fairly	evenly	across	the	different	
services,	with	a	slightly	lower	rate	seen	in	Anesthesiology	(all	PG-Year	1).	
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Q23:	I	am	knowledgeable	about	Naloxone	
	
	
Q23	–	This	question	asks	if	the	resident	is	knowledgeable	about	Naloxone.	The	responses	are	
fairly	similar	to	the	previous	question,	also	favoring	agreement.	Agree	and	strongly	agree	
responses	appear	in	53	cases	(51%);	disagree	and	strongly	disagree	appear	16	times	(16%),	with	
34	neutral	responses	(33%),	which	if	added	together,	yield	49%	who	do	not	feel	especially	
knowledgeable.	These	50	cases	are	similarly	distributed	fairly	evenly,	with	a	lower	rate	in	
Anesthesiology	(almost	all	in	PG-Year	1).	 	
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Q24-27	Availability	
	
	
	
Q24:	Naloxone	should	be	available	to	all	patients	
	
	
	
	
Q25:	Naloxone	should	only	be	available	to	patients	that	use	opioids	
	 32	
	
Q24	–	This	group	of	questions	focuses	on	Naloxone	availability.	Q24	asks	if	Naloxone	should	be	
made	available	to	all	patients.	There	is	strong	agreement	with	this	statement;	a	total	of	80	
respondents	(78%)	agree	or	strongly	agree	with	the	statement.	In	contrast,	only	10	(10%)	
disagree	or	strongly	disagree,	while	13	(13%)	of	respondents	are	neutral.	The	disagrees	and	
neutral	responses	are	scattered	fairly	evenly	across	disciplines,	perhaps	a	bit	higher	in	Surgery.	
	
Q25	–	The	next	question	in	this	group	ask	whether	Naloxone	should	be	available	only	to	
patients	that	use	opioids.	Here	there	is	significant	disagreement—61	respondents	(59%)	
disagree	or	strongly	disagree	with	the	statement,	while	only	18	(17%)	agree	or	strongly	agree,	
and	24	responses	(23%)	are	neutral.	The	agree/strongly	agree	responses	are	generally	scattered	
fairly	evenly	across	all	services,	though	a	bit	higher	in	Surgery,	and	not	present	in	Internal	
Medicine,	Pediatrics,	Radiation	Oncology,	nor	Radiology.	
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Q26:	Naloxone	should	be	available	to	friends	and	family	members	of	patients	that	use	opioids	
	
	
	
	
Q27:	Naloxone	is	easy	for	patients	to	obtain	
	 34	
	
Q26	–	Question	26	asks	whether	Naloxone	should	be	made	available	to	family	and	friends	of	
opioid	patients.	Here	again,	there	is	very	strong	agreement	with	the	statement.	A	total	of	90	
respondents	(87%)	agreed	or	strongly	agreed;	only	2	(2%)	disagreed,	with	11	(11%)	neutral	
responses.	
	
Q27	–	The	last	question	in	this	group	asks	whether	Naloxone	is	easy	for	patients	to	obtain.	The	
most	common	response	here	is	neutral	(52	or	50%),	perhaps	indicating	a	lack	of	information	for	
making	a	judgement.	Of	the	rest,	38	(37%)	disagree	or	strongly	disagree	with	the	statement,	
while	only	13	(13%)	agree	or	strongly	agree.	The	agree/strongly	agree	responses	were	most	
common	in	Anesthesiology,	Internal	Medicine,	and	Psychiatry.	
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Q28-31	Confidence	
	
	
	
Q28:	I	feel	comfortable	prescribing	Naloxone	to	patients	
	
	
	
	
Q29:	I	can	confidently	identify	patients	that	would	benefit	from	being	prescribed	Naloxone	
	 36	
	
Q28	–	This	question	asks	if	residents	feel	comfortable	prescribing	Naloxone.	Overall	the	results	
are	affirmative;	46	respondents	(45%)	agree	or	strongly	agree,	while	33	(32%)	disagree	or	
strongly	disagree.	The	remaining	24	(23%)	are	neutral—also	an	indication	of	some	degree	of	
discomfort,	so	one	could	say	that	over	half	(55%)	do	not	definitively	feel	comfortable	
prescribing	Naloxone.	The	two	disagrees	and	neutral	answers	are	clustered	in	Pediatrics,	
Radiation	Oncology,	and	Surgery,	and	mixed	in	Anesthesiology	and	Internal	Medicine—the	
former	with	more	disagrees	and	the	latter	with	more	agrees.	Otherwise,	results	are	fairly	
mixed,	except	for	Psychiatry,	which	had	the	highest	percentage	of	agree/strongly	agree	
responses	(80%).	
	
Q29	–	The	next	question	asks	whether	a	resident	can	confidently	identify	patients	that	would	
benefit	from	Naloxone.	Here	the	number	of	agreement	responses	is	sharply	reduced.	There	are	
31	(30%)	agree	or	strongly	agree	responses,	versus	33	(32%)	disagree	or	strongly	disagree	
responses.	The	most	common	response	is	‘neutral’	(39,	or	38%),	again	indicating	some	lack	of	
comfort.	Adding	these	to	the	two	disagree	responses	gives	70%	who	are	not	particularly	
confident	about	identifying	Naloxone	candidate	patients.	By	discipline,	these	are:		
Anesthesiology	–	63%,	Dermatology	–	0	of	1,	Family	Medicine	–	2	of	3,	Internal	Medicine	–	80%,	
IM-Pediatrics	–	4	of	5,	Neurology	–	2	of	3,	Obstetrics/Gyn	–	3	of	3,	Orthopedic	Surgery	–	1	of	4,	
Pediatrics	–	86%,	Physical	Medicine	–	83%,	Psychiatry	–	27%,	Radiation	Oncology	–	2	of	2,	
Radiology	–	2	of	2,	Surgery	–	100%,	and	Urology	–	1	of	1.	
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Q30:	I	have	the	necessary	knowledge	required	to	explain	to	a	patient	how	to	use	Naloxone	
	
	
	
	
Q31:	I	feel	comfortable	explaining	to	a	patient	how	to	use	Naloxone	
	 38	
	
Q30	–	Continuing	in	the	same	vein,	Q30	asks	about	having	the	knowledge	to	explain	Naloxone	
use.	There	are	29	(28%)	agrees	or	strongly	agrees,	versus	51	(50%)	disagree/strongly	disagree,	
and	23	(22%)	neutral.	Disagree	is	the	most	common	response	here	(42	or	41%).	If	the	neutrals	
are	combined	with	the	disagrees,	this	gives	72%	that	do	not	clearly	feel	they	have	the	required	
knowledge.	Again	by	discipline:		Anesthesiology	–	54%,	Dermatology	–	1	of	1,	Family	Medicine	–	
2	of	3,	Internal	Medicine	–	80%,	IM-Pediatrics	–	4	of	5,	Neurology	–	2	of	3,	Obstetrics/Gyn	–	3	of	
3,	Orthopedic	Surgery	–	1	of	4,	Pediatrics	–	100%,	Physical	Medicine	–	67%,	Psychiatry	–	63%,	
Radiation	Oncology	–	2	of	2,	Radiology	–	1	of	2,	Surgery	–	80%,	and	Urology	–	1	of	1.	The	biggest	
downward	change	here	was	for	Psychiatry	(27%	for	Q29,	63%	for	Q30).	
	
Q31	–	The	final	question	in	this	group	asks	about	feeling	comfortable	explaining	Naloxone	use.	
These	responses	are	similar	to	the	previous	question;	there	are	26	(25%)	agree/strongly	agree	
responses,	55	(54%)	disagree/strongly	disagree	responses,	and	22	(21%)	neutral	responses.	
Combining	the	disagrees	with	the	neutrals,	we	get	75%	of	respondents	who	do	not	expressly	
feel	comfortable	explaining	Naloxone	use	to	patients.	The	results	for	each	discipline	are	largely	
the	same	as	for	Q30,	with	only	minor	differences	(+-1)	in	several	of	them.	
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Q32-33	Institutional	Setting	
	
	
	
Q32:	Naloxone	is	prescribed	frequently	at	my	institution	in	the	inpatient	setting	
	
	
	
	
Q33:	Naloxone	is	prescribed	frequently	at	my	institution	in	the	outpatient	setting	
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Q32	–	Question	32	asks	if	Naloxone	is	frequently	prescribed	in	an	inpatient	setting.	The	most	
common	answer	was	‘Neutral’	(38	or	37%	of	the	103	total),	perhaps	reflecting	a	lack	of	
information	for	making	a	definitive	judgement.	The	most	neutral	responses	were	found	in	
Anesthesiology	(12	or	50%	of	the	program	responses).	Overall,	the	responses	were	more	
negative	than	positive;	44	(42%)	either	disagreed	or	strongly	disagreed	with	the	statement,	
while	only	21	(20%)	agreed	or	strongly	agreed.	More	definitive	answers	were	found	in	Internal	
Medicine,	Physical	Medicine,	and	Surgery,	plus	Radiation	Oncology.	Other	than	that,	the	
responses	were	fairly	mixed	through	all	disciplines.	
	
Q33	–	Question	33	asks	the	same	question,	but	for	the	outpatient	setting.	The	overall	pattern	is	
similar,	but	there	is	overall	stronger	disagreement	in	this	case.	Again	‘Neutral’	was	the	most	
common	response	(49	or	48%	of	103	respondents,	11	more	than	for	Q32).	The	largest	number	
of	these	was	found	in	Anesthesiology	(17	or	71%	of	that	group);	high	percentages	were	also	
found	in	Pediatrics,	Psychiatry	and	Surgery.	An	equivalent	number	(49)	either	disagreed	or	
strongly	disagreed	with	the	statement,	and	only	5	either	agreed	or	strongly	agreed.	Other	than	
this,	the	results	were	mixed.	
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Q34-35	Naloxone	Risks	
	
	
	
Q34:	Naloxone	encourages	patients	that	misuse	opioids	to	use	them	in	an	addictive	manner	
	
	
	
	
Q35:	Naloxone	enables	drug	use	and	should	not	be	provided	
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Q34	 - Naloxone	 Encourages	Addictive	 Opioid	 Misuse?
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Q34	–	Question	34	shows	significant	overall	disagreement	with	the	idea	that	Naloxone	
encourages	patients	to	use	opioids	in	an	addictive	manner.	A	total	of	80	respondents	(78%)	
either	disagreed	or	strongly	disagreed	with	the	statement;	another	20	(19%)	were	neutral	
responses,	and	there	were	only	3	agreements.	Most	of	the	strong	disagreements	were	found	in	
Anesthesiology,	Internal	Medicine,	Psychiatry,	and	Surgery,	as	well	as	Radiology.	
	
Q35	–	The	final	question,	on	whether	Naloxone	actually	enables	drug	use,	had	an	even	stronger	
disagreement	response	than	the	previous	question.	A	total	of	88	respondents	(85%)	either	
disagreed	or	strongly	disagreed	with	the	statement,	solidly	rejecting	the	enabling	view.	The	
remaining	15%	were	all	neutral	responses;	there	were	no	agreements.	The	largest	rate	of	
neutral	responses	were	found	in	Surgery	(30%),	and	Anesthesiology	(21%).	Especially	high	rates	
of	strong	disagreement	(>60%	of	program	respondents)	within	the	larger	groups	were	found	in	
Internal	Medicine,	IM-Pediatrics,	and	Pediatrics,	as	well	as	in	Radiology	and	Radiation	Oncology.	
	
	
	
	
	 	
	 43	
Conclusion	
	
As	noted	in	the	Introduction,	the	purpose	of	this	study	was	to	ascertain	the	attitudes	of	
residents	towards	Naloxone	and	their	prescription	practices,	as	well	as	analyze	if	there	were	
specific	differences	between	residencies	on	these	topics.	Given	that	the	number	of	respondents	
was	103	out	of	735	residents	(14%),	it	is	difficult	to	draw	definitive	conclusions	regarding	
individual	residency	programs	(especially	for	those	which	had	5	or	fewer	residents	responding).	
However,	despite	this	limitation	some	conclusions	can	be	gathered,	certainly	within	the	
confines	of	the	responses	received.	
	
It	is	true	that	many	of	the	differences	cited	between	residency	responses	for	the	larger	groups	
can	likely	be	explained	by	differences	in	patient	populations	and	the	medical	services	provided	
by	different	programs.	Nevertheless,	observed	differences	in	terms	of	knowledge,	training,	
comfort,	and	experience	concerning	Naloxone	administration	and	prescribing,	may	also	suggest	
areas	or	targets	for	additional	attention	or	educational	interventions.	
	
The	first	part	of	the	study,	focused	on	prescription	practices	of	residents,	showed	that	slightly	
more	than	half	of	the	respondents	have	been	trained	to	use	Naloxone	in	an	overdose	situation,	
but	less	than	half	in	how	to	prescribe	it.	Still	fewer	have	actually	administered	or	prescribed	
Naloxone.	This	despite	having	many	of	their	patients	struggling	with	opioids	and	in	need	of	
overdose	prevention	measures.	
	
A	similar	pattern	was	seen	in	the	second	part	of	the	study,	concerning	the	resident	attitudes	
toward	Naloxone,	where	across	the	board	residents	had	a	favorable	opinion	toward	Naloxone,	
but	were	unfamiliar	or	uncomfortable	prescribing	it	to	their	patients.	Nearly	all	(95%)	of	
respondents	view	Naloxone	as	a	potential	lifesaving	intervention,	but	only	half	feel	comfortable	
administering	it,	or	feel	knowledgeable	about	it.	There	is	very	strong	agreement	that	Naloxone	
does	not	encourage	addictive	opioid	misuse	and	does	not	enable	drug	use,	and	likewise	that	it	
should	be	available	to	all	patients	(not	just	opioid	patients),	as	well	as	to	friends	and	family	
members—and	that	Naloxone	is	not	currently	easy	for	patients	to	obtain.	Yet,	when	asked	if	
they	have	the	knowledge	to	explain	Naloxone	use,	and	feel	comfortable	doing	so,	we	see	that	
70-75%	say	no	or	equivocate,	and	over	half	do	not	feel	comfortable	prescribing	Naloxone.	
Perhaps	most	important,	70%	do	not	feel	they	can	confidently	identify	patients	who	would	
benefit	from	being	prescribed	Naloxone.	Surely	it	is	possible	to	do	better	than	this.	
	
Recently,	the	AMA	Opioid	Task	Force	issued	updated	guidance	“encouraging	physicians	to	
consider	co-prescribing	Naloxone	when	clinically	appropriate	for	patients	who	are	at	risk	for	
opioid	overdose	or	might	be	able	to	help	someone	at	risk.”	In	the	same	article,	Dr.	Sarah	
Wakeman	states	“co-prescribing	Naloxone	is	important	to	ensure	all	people	being	prescribed	
opioids	at	risk	for	overdose	have	this	lifesaving	medication	at	home,	similar	to	how	we	might	
think	about	co-prescribing	glucagon	to	someone	with	insulin-dependent	diabetes”	(9).		
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Thus,	given	the	scope	of	opioid-related	deaths	in	this	country,	it	is	essential	that	the	residents	
of	the	University	of	Michigan	Medical	School	of	all	disciplines	be	exposed	to	Naloxone	
education	and	feel	comfortable	prescribing	it	when	necessary.	Indeed,	a	study	just	performed	
in	2018	showed	that	a	brief	curricular	intervention	among	medical	residents	at	an	urban,	
tertiary	medical	center	improved	their	knowledge,	attitudes,	and	comfort	levels	toward	
Naloxone,	and	significantly	increased	their	prescribing	rates	(12).	This	type	of	approach	should	
be	given	consideration	at	UMMS.	
	
	
In	closing,	I	wish	to	thank	Dr.	Jouney	for	his	advice	and	assistance	throughout	the	project	and	
Dr.	Jibson	for	his	help	and	guidance.	I	am	also	grateful	to	all	residency	program	directors	for	
their	support	as	well	as	to	the	residents	who	took	the	time	to	complete	the	survey.	
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